Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Jain P , Thompson PA , Keating M , Estrov Z , Ferrajoli A , Jain N , Kantarjian H , Burger JA , O'Brien S , Wierda WG 
Cancer.2017 Feb 07 ; ():.
PubMedで表示
Google翻訳で開く
(14view , 0users)
Full Text Sources
Medical
Other Literature Sources
Ibrutinib is a Bruton tyrosine kinase inhibitor and is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) in frontline and relapsed/refractory settings. The authors previously reported poor outcomes for patients who discontinued ibrutinib; however, long-term outcomes were not reported.
PMID: 28171709 [PubMed - as supplied by publisher]
PMID: 28171709 [PubMed - as supplied by publisher]
関連論文
- Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib.
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
- Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
- [Review] Ibrutinib for treatment of chronic lymphocytic leukemia.
- Real--world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program.